Pila Pharma

Pila Pharma AB is a clinical stage biotech company listed at Nasdaq First North GM, Stockholm Sweden that develops a TRPV1 antagonist, XEN-D0501, as a new type of treatment of diabetes and potentially obesity.

Currently, a phase 2a clinical trial application is being prepared to study the safety and tolerability (and trend for effect on blood glucose and bodyweight) following 3 months treatment with XEN-D0501 in overweight or obese persons with diabetes.

Millionærklubben by EuroInvestor [14. November 2024]

CEO Gustav H. Gram participates in Denmark’s largest finance and investment podcast to elaborate on PILA PHARMA and discuss the emerging trends within the obesity and diabetes market.

Please, find the link to the video (in Danish) here

Interim Report First Half Year 2024, 1 January – 30 June 2024

Read the report PDF (in English) here

ARTICLES:

Aktie.info Danmark Analyse af Pila Pharma

2. analyse – Pila Pharma Halvårsrapport 2024 (September 30, 2024)

Read the report PDF (in Danish) here

SEPT 18: Svenska Dagbladet Tema: Innovation, Vård & Life Science:

Innovativt läkemedel för typ-2 diabetes och övervikt är nära.

Read the report (in Swedish) here

Sept 12: Børsen / Berlingske Tidende Tema:

Pila Pharma baner vejen for nye tanker om behandling af diabetes og fedme.

Read the report PDF (in Danish) here

SEPT 06: Nordic Life Science Magazine:

Pila Pharma raises capital for international obesity study.

Read the report (in English) here

PRESENTATIONS AND INTERVIEWS:

PILA PHARMA STOKK.io After-Work Q&A [October 28, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram hosts an investor after-work Q&A specifically tailored with investor questions collected from different Stock trading forums and PILA PHARMA’s social media platforms.

In this session he answers questions from investors that touches upon the status, happenings and other things such as the market and global trends for Diabetes, Obesity and Cardiovascular disease, disease areas that PILA aims to address.

The Q&A was held together with moderator Anders Egsvang Rasmussen from Stokk.io, a platform that facilitates investor reach for companies.

The Q&A is conducted in English here

PILA PHARMA, REDEYE, Cardiovascular & Metabolic day [October 17, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in an online Investor Forum with Redeye and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Einarsson, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovascular disease that PILA aims to tap into.

The presentation & Q&A is conducted (in English) here

PILA PHARMA x REDEYE H1 Report & Q&A [August 29, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in a online Investor Forum with Redeye and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Einarsson, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovasculardisease that PILA aims to tap into.

The presentation & Q&A is conducted (in English) here

PILA PHARMA x AKTIESPARARNA – H1 Report & Q&A [August 28, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in a online Life Science evening with Aktiespararna and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Lindkvist, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovascular disease that PILA aims to tap into.

The presentation & Q&A is conducted (in English) here

PILA PHARMA x Stokk.io – H1 Report & Q&A [August 27, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram hosts a webinar with Stokk.io and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with investor questions about PILA PHARMA. In this questions about the market and global trends for Diabetes, obesity and cardiovascular disease that PILA aims to tap into are answer.

The presentation & Q&A is conducted (in English) here

International Diabetes & Nutrition Symposia, June 29th

Founder, Inventor, CSO and Chairman of PILA PHARMA, Dr. Dorte X. Gram presents the short PILA PHARMA story and rationale behind treatment of metabolic conditions with a TRPV1 / Capsaicin receptor antagonist, to the DNSG 2024 Symposium, the 41st International Symposium on Diabetes and Nutrition, which took place in Uppsala, Sweden on June 27th – 30th, 2024.

Please, find the link to the video (in English) here

The CEO of Pila Pharma was recently interviewed by Vækstaktier, Denmark about his participation in BIO INTERNATIONAL CONVENTION 2024, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe.

Find the link to the article and other articles about Pila Pharma (in Danish) on Vækstaktier.dk

Aktiespararna June 12th, 2024

PILA PHARMA’s CEO, Mr. Gustav H. Gram presents the company.

Please, find the link to the video (in English) here

Pila Pharma Redeye Diabetes Day May 23rd, 2024

PILA PHARMA’s CEO, Mr. Gustav H. Gram provides an insight into the market and global trends for Diabetes, obesity and cardiovascular disease that PILA aims to tap into. The presentation and Q&A is conducted in English.

Please, find the link to the video (in English) here

Stokk.io April 22nd, 2024

Newly appointed CEO, Gustav H. Gram, hosts a Q&A with Stokk.io on PILA PHARMA’s changes with Founder Dorte X. Gram transitioning to Chairman of the Board and what changes and direction that investors can expect. The Q&A is conducted in English together with Anders Egsvang from Stokk.io

Please, find the link to the video (in English) here

We were incredibly honoured that the American Diabetes Association(ADA) featured PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.

In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes.
Thank you so much to our scientific advisors Mark Evans and Jens Juul Holst for helping our previous CEO explain!

Watch the video (in English) here

See the latest Presentations and Interviews here

Read the latest Press Releases here